MCLA-129
Solid Tumors
About Merus
Merus is a clinical-stage biotech focused on closing in on cancer by discovering and developing novel multispecific antibody therapeutics. The company's core asset is its proprietary Multiclonics® platform, which enables the creation of full-length, human IgG bispecific and trispecific antibodies with manufacturing and pharmacokinetic profiles akin to conventional monoclonal antibodies. Merus has built a robust, wholly-owned and partnered clinical pipeline, with its lead candidate, petosemtamab, in Phase 3 development for head and neck cancer. The company's recent acquisition by and integration into Genmab represents a pivotal strategic shift, providing enhanced resources and a broader platform to accelerate its ambitious oncology programs.
View full company profileAbout Merus
Merus is a clinical-stage biotech focused on closing in on cancer by discovering and developing novel multispecific antibody therapeutics. The company's core asset is its proprietary Multiclonics® platform, which enables the creation of full-length, human IgG bispecific and trispecific antibodies with manufacturing and pharmacokinetic profiles akin to conventional monoclonal antibodies. Merus has built a robust, wholly-owned and partnered clinical pipeline, with its lead candidate, petosemtamab, in Phase 3 development for head and neck cancer. The company's recent acquisition by and integration into Genmab represents a pivotal strategic shift, providing enhanced resources and a broader platform to accelerate its ambitious oncology programs.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |